Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,789 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07044687 | Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | recruiting | Phase 4 | 100 | AbbVieINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07773909 | Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy | completed | Phase 4 | 24 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER |
| 1 |
| Aug 21, 2026 |
| clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT05853458 | Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors(HU-F-AIM) | terminated | Phase 4 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | recruiting | Phase 4 | 16 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06290765 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera(PV) | withdrawn | Phase 4 | 0 | PharmaEssentiaINDUSTRY | 0 | Jul 31, 2026 | clinicaltrials |
| NCT06289673 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | recruiting | Phase 4 | 850 | St. Jude Children's Research HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT06370000 | Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality(REMAIN1) | recruiting | Phase 4 | 12 | Virginia Commonwealth UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07561892 | Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).(AML) | recruiting | Phase 4 | 100 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06748001 | Avapritinib Rollover Study | recruiting | Phase 4 | 60 | Blueprint Medicines CorporationINDUSTRY | 6 | Feb 9, 2026 | clinicaltrials |
| NCT07016165 | Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies | recruiting | Phase 4 | 120 | Gadjah Mada UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07105319 | Ropeginterferon for Treatment Free Remission(ROPEG) | completed | Phase 4 | 65 | Dong-Wook KimOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT02926586 | Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML | completed | Phase 4 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06571825 | RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR | recruiting | Phase 4 | 118 | He HuangOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT04155411 | Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP | unknown | Phase 4 | 65 | Shenzhen Second People's HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02546674 | Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.(NILOdeepR) | completed | Phase 4 | 171 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02200978 | A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | completed | Phase 4 | 176 | South China Children's Leukemia GroupOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | not yet recruiting | Phase 4 | 2,400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT00980018 | An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment(MACS0999) | completed | Phase 4 | 52 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 1, 2021 | clinicaltrials |
| NCT01131325 | Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations(MACS1148) | terminated | Phase 4 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | May 20, 2021 | clinicaltrials |
| NCT04636918 | Ikervis for DED Due to GVHD Post Allo-HSCT(Ikervis) | unknown | Phase 4 | 40 | Singapore Eye Research InstituteOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT03176849 | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | completed | Phase 4 | 49 | Phoenix Children's HospitalOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02875743 | King's Invasive Aspergillosis Study II | completed | Phase 4 | 120 | King's College Hospital NHS TrustOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT01243489 | Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation(Crescendo) | completed | Phase 4 | 104 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT01201811 | Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) | completed | Phase 4 | 44 | CelgeneINDUSTRY | 1 | Dec 5, 2019 | clinicaltrials |
| NCT01578213 | Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients(ISAV) | completed | Phase 4 | 112 | University of Milano BicoccaOTHER | 5 | Dec 3, 2019 | clinicaltrials |
| NCT00003398 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 4 | 45 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01987297 | Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL | unknown | Phase 4 | 738 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT02933333 | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | unknown | Phase 4 | 405 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT02204722 | A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients(IDEAL) | terminated | Phase 4 | 55 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01200355 | Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome | completed | Phase 4 | 113 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 7, 2018 | clinicaltrials |
| NCT01819792 | Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia(LAMVIRE) | completed | Phase 4 | 119 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01347996 | Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia | completed | Phase 4 | 84 | Cytovia, Inc.OTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT03332511 | Efficacy and Safety of Nilotinib in CML-CP(ENESTKorea) | completed | Phase 4 | 110 | Seoul National University HospitalOTHER | 0 | Nov 6, 2017 | clinicaltrials |
| NCT03216070 | Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia | unknown | Phase 4 | 12 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT03150134 | Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients | unknown | Phase 4 | 100 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT01605981 | Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.(MACS1881) | withdrawn | Phase 4 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00686543 | Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) | completed | Phase 4 | 75 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT02086487 | Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy(NISRI) | terminated | Phase 4 | 98 | King Abdullah International Medical Research CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | completed | Phase 4 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01206088 | Tasigna in Glivec-resistant or Intolerant Patients in CML | completed | Phase 4 | 93 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00171899 | Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) | completed | Phase 4 | 80 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00786812 | Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(MACS0439) | completed | Phase 4 | 89 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT03026842 | Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) | unknown | Phase 4 | 180 | The First Hospital of Jilin UniversityOTHER | 1 | Jan 20, 2017 | clinicaltrials |
Data updated 18 days agoSource updated Sep 11, 2026source: clinicaltrials